Free Trial

Stoke Therapeutics (STOK) Stock Forecast & Price Target

Stoke Therapeutics logo
$11.68 +0.38 (+3.36%)
(As of 12/20/2024 05:31 PM ET)

Stoke Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
9

Based on 10 Wall Street analysts who have issued ratings for Stoke Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 10 analysts, 1 has given a hold rating, 8 have given a buy rating, and 1 has given a strong buy rating for STOK.

Consensus Price Target

$21.29
82.24% Upside
According to the 10 analysts' twelve-month price targets for Stoke Therapeutics, the average price target is $21.29. The highest price target for STOK is $35.00, while the lowest price target for STOK is $13.00. The average price target represents a forecasted upside of 82.24% from the current price of $11.68.
Get the Latest News and Ratings for STOK and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Stoke Therapeutics and its competitors.

Sign Up

STOK Analyst Ratings Over Time

TypeCurrent Forecast
12/23/23 to 12/22/24
1 Month Ago
11/23/23 to 11/22/24
3 Months Ago
9/24/23 to 9/23/24
1 Year Ago
12/23/22 to 12/23/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$21.29$20.83$21.40$21.00
Forecasted Upside82.24% Upside82.27% Upside61.27% Upside294.00% Upside
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy

STOK Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STOK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stoke Therapeutics Stock vs. The Competition

TypeStoke TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside82.24% Upside25,827.32% Upside14.53% Upside
News Sentiment Rating
Positive News

See Recent STOK News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/20/2024Chardan Capital
1 of 5 stars
R. Li
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$24.00+112.39%
12/10/2024Cantor Fitzgerald
4 of 5 stars
 Reiterated RatingOverweight ➝ Overweight
11/6/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00+68.58%
11/6/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$35.00 ➝ $35.00+168.20%
10/14/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$18.00+52.03%
10/11/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/11/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00+20.48%
5/7/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$21.00 ➝ $20.00+67.22%
3/26/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform
3/26/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$6.00 ➝ $13.00+100.00%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$23.00+293.16%
5/1/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$9.00 ➝ $12.00+34.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 08:30 PM ET.


STOK Forecast - Frequently Asked Questions

According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Stoke Therapeutics is $21.29, with a high forecast of $35.00 and a low forecast of $13.00.

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There is currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STOK shares.

According to analysts, Stoke Therapeutics's stock has a predicted upside of 82.24% based on their 12-month stock forecasts.

Over the previous 90 days, Stoke Therapeutics's stock had 1 upgrade by analysts.

Stoke Therapeutics has been rated by research analysts at Cantor Fitzgerald, Chardan Capital, HC Wainwright, Leerink Partners, Leerink Partnrs, and Needham & Company LLC in the past 90 days.

Analysts like Stoke Therapeutics more than other "medical" companies. The consensus rating for Stoke Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how STOK compares to other companies.


This page (NASDAQ:STOK) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners